Valeant Offers New Psoriasis Drug for $3,500/Month

Apr 21, 2017

Canada's Valeant Pharmaceuticals International priced its soon-to-be-released plaque psoriasis treatment at $3,500 per month, ahead of its U.S. launch coming in the second half of 2017.

Valeant says Siliq is the lowest priced injectable biologic psoriasis treatment currently on the market.

The treatment blocks a cell receptor known as interleukin-17, and it will compete with a many existing IL-17 inhibitors including Cosentyx from Novartis AG and Taltz from Eli Lilly & Co, according to a Reuters article.

Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments